About PeptideFox
Demystifying Peptide Research — Translating the Evidence
Editorial & Medical Review: FoxAI Biomedical Research Team
At PeptideFox, we prioritize intellectual integrity above all else, applying a strict standard to research — always referenced and contextualized. Unlike many other sources of information, we apply equal scrutiny to peer-reviewed, pharmaceutical-sponsored publications as we do to academic mechanistic evidence.
We conduct high-resolution research — which means going beyond polished headline papers and applying scrutiny to claims by extracting and tabulating data from registered clinical trials and supplementary appendices, where critical information on adverse events, phenotype specific responses, and week-by-week data on efficacy and results is often buried.
PeptideFox conducts primary research on real-world-evidence (RWE) of peptides, building off the ground-breaking work on curation and extraction of drug-related entities from public forums by Wang et al. 2026 at Cornell University and Duan & Wei 2025 at the University of Michigan and University of Pennsylvania.
- Lead researcher & data integrity reviewer
- Former McKinsey analyst with extensive experience working with the World Health Organization (WHO) — published in peer-reviewed science journals ( BMC Chemistry, Springer Nature) and through the McKinsey Global Institute.
- Clinical & medical reviewer
- Board-certified physician and Assistant Clinical Professor at Michigan State University, holding an M.D. from Georgetown University and completed residency at Ronald Reagan UCLA Medical Center.
Review standards
- Research and data integrity
- Numbers are checked against primary papers, registered trials, supplementary appendices, and regulatory source documents. Conflicts between headline claims and underlying tables are resolved in favor of the underlying data.
- Medical review
- Safety claims, adverse events, contraindications, and clinical context are reviewed before a page receives a medical-review date.
- Source hierarchy and evidence status
- Direct human evidence comes first, followed by mechanistic and pre-clinical evidence. Practitioner observation is labeled as observation, and combinations without direct trials are labeled as untested combinations.
- Last reviewed
- “Last reviewed” means the page completed both research/data-integrity review and medical review on that date. A substantive update after that date removes the reviewed status until the page is reviewed again.
- Corrections
- Source, calculation, and interpretation corrections can be submitted through PeptideFox support. Corrections are checked against the cited source before publication.
Review date appears only on pages that have gone through the full process of both data-integrity review and medical review.
The State of Medical Research
High-resolution research is an orientation toward applying intellectually honest scrutiny to all research — whether that be pre-clinical academic research or peer-reviewed publications covering clinical trials. While the former is often more straightforward, as the lack of evidence is easier to identify, the latter presents a more complex challenge that requires going beyond the headlines.
"Afflicted by studies with small sample sizes, tiny effects, invalid exploratory analyses, and flagrant conflicts of interest, together with an obsession for pursuing fashionable trends of dubious importance, science has taken a turn towards darkness. As one participant put it, “poor methods get results”. The Academy of Medical Sciences, Medical Research Council, and Biotechnology and Biological Sciences Research Council have now put their reputational weight behind an investigation into these questionable research practices. The apparent endemicity of bad research behaviour is alarming.
In their quest for telling a compelling story, scientists too often sculpt data to fit their preferred theory of the world. Or they retrofit hypotheses to fit their data. Journal editors deserve their fair share of criticism too. We aid and abet the worst behaviours. Our acquiescence to the impact factor fuels an unhealthy competition to win a place in a select few journals. Our love of “significance” pollutes the literature with many a statistical fairy-tale."
For additional information, refer to the work of Marcia Angell — the former editor-in-chief of the New England Journal of Medicine and senior lecturer at Harvard Medical School — who has written about the subject for over a decade in the New York Review of Books and in her 2004 book, The Truth About Drug Companies and John P.A. Ioannidis — the George E. and Lucy Becker Professor of Medicine, Professor of Epidemiology and Population Health and Biomedical Data Science at Stanford University.
Peptides in the Context of Modern Medical Science
Modern medicine is extraordinary at saving your life. Surgery, oncology, infectious disease — when the problem is discrete, single-target interventions work. The regulatory system governing them makes sense.
But living a healthy, functional life is not a discrete problem. Metabolic health, immune regulation, tissue repair, sleep architecture — these are integrated systems. The regulatory framework built for acute care evaluates single drugs targeting single endpoints.
This is not a conspiracy. It is the byproduct of institutional economics and the inertia of a system with a complex web of actors.
FDA approval requires a sponsor willing to fund $1–2 billion in trials. Sponsors invest only when patent protection guarantees returns. Natural peptides — the signaling molecules your body already uses to coordinate repair, metabolism, and immunity — cannot be patented. No rational actor will spend billions to validate a compound competitors can manufacture the next day.
The compounds most mechanistically aligned with human biology are the poorest fit for the economics that govern access to them.
Evidence Landscape of Peptides
Across PeptideFox, we lay out the evidence status of each compound unambiguously. To not do so would violate our core principle of intellectual integrity.
FDA-approved / in pipeline
GLP-1 agonists (semaglutide, tirzepatide), SS-31 (elamipretide), tesamorelin. Established safety profiles. Phase III data for specified trial-populations. Retatrutide is in the FDA pipeline — with approval expected in early 2027.
Extensive human data in academic and/or international research
Thymosin Alpha-1 (approved in 35+ countries), NAD+ precursors (multiple clinical trials, broad clinical use), Vasoactive Intestinal Peptide (multiple Phase II and Phase III trials). As naturally occurring compounds, these lack a path to commercialization through the FDA pipeline.
Emerging
International trials (Thymosin Beta 4, Phase II) and MOTS-c (Phase I)
Pre-clinical
Mechanistic research and pre-clinical data (cell culture, animal models), with strong biological plausibility, but no human trials (KPV, 5-Amino-1MQ). Others with pre-clinical data and limited case study reports by medical doctors (BPC-157). Others from Russia with extensive pre-clinical data (Pinealon), and those corroborated by Western research (Epitalon).
Frequently Asked Questions
What is PeptideFox?
PeptideFox is an independent biomedical research and software publisher focused on distilling clinical data and systems-biology through evidence-based guides and tools, enabling anyone with a high-school biology education to understand peptides — without overstating unproven benefits or glossing over risks.
What tools does PeptideFox provide?
In an age where low-quality AI-generated peptide apps are flooding the market, PeptideFox focuses on providing tools rooted in accuracy with a thoughtful UX and elevated design: a no-guesswork reconstitution calculator that solves BAC water volume for accurate and easy dosing of individual peptides and peptide blends, GLP-1 dosing tools that accurately model drug exposure, protocol guides that lay out dosing schedules, timelines, side effects, and contraindications — plus evidence-backed in-depth explainers for over 30 compounds on the web and through the PeptideFox iOS app.
PeptideFox also develops FoxAI — a peptide-focused AI that answers from an extensive knowledge corpus of high-resolution data (web only; iOS app launching in August 2026).
How is PeptideFox different from other peptide information and clinical platforms?
The information landscape surrounding peptides in 2026 is fractured. On one end, there is jargon-laden academic literature and clinical data, largely inaccessible to most. On the other, there is what is commonly referred to as 'AI slop' (re-packaged LLM responses and generated content) coupled with 'bro-science' (i.e. Reddit group think), where information is at best surface-level, and at worst, entirely hallucinated or false. PeptideFox exists to fill that gap by going beyond the headlines, diving into and extracting clinical data at the highest resolution, and merging it with peer-reviewed systems-biology research — distilling that information by translating jargon into plain-speak, classifying evidence quality, and laying out data through easy to understand tables and charts. PeptideFox is not a clinical platform — it is filling a crucial information gap, with harm reduction as a driving principle.
What is high-resolution research?
High-resolution research preserves the details that change what a result means. Most medical and peptide information sources — including highly credible ones — regurgitate headline results from Phase II/Phase III clinical trials.
PeptideFox goes deeper by incorporating data from paper supplements, ClinicalTrials.gov, and Phase I safety and pharmacological discovery studies — and painstakingly extracting un-tabulated data from charts buried in various appendices that contain weekly or daily datapoints, cohort breakout details, and crucial side-effect breakdowns. This information is critical to interpret clinical data correctly, rather than callously reducing complex biology and pharmacological interactions into a 'one-size-fits-all' model. Clinical trial data, mechanistic research, and real-world evidence (RWE) have different methodologies and answer different questions — each is used only for the claims it can support.
High-resolution research applies scrutiny across the board — and always views results through the lens of the studied population. For example, if a GLP-1 weight loss drug grouped participants by BMI — a controversial and flawed directional marker of metabolic health — and the cohort with the 2nd highest terminal dose showcased the strongest results, we may find that cohort also happened to have a disproportionate amount of women, who weighed less on average and skewed younger, which would increase their total drug exposure (mg/kg) as well as the downstream effects due to a healthier metabolic baseline.
In the case of RWE, adverse-event data extracted from online forums (i.e. Reddit) can reveal symptom vocabulary, timing, and patterns that trial questionnaires did not capture. But that data cannot establish population incidence when the denominator consists of symptom-disclosing users who are more likely to self-report and/or demographic data is entirely absent.
Who researches and reviews PeptideFox content?
The FoxAI Biomedical Research Team produces and reviews PeptideFox content. The lead researcher — a former McKinsey analyst with experience working with the WHO and published in *BMC Chemistry, Springer Nature* — is responsible for data extraction / dataset construction and reserach synthesis. The clinical and medical reviewer, an Assistant Clinical Professor at Michigan State University, checks safety claims, adverse events, contraindications, and clinical context before a page receives a medical-review date.
What is FoxAI, and how is it different from popular AI tools like ChatGPT, Gemini, and Claude?
FoxAI is the research assistant LLM inside PeptideFox. Its answers draw from PeptideFox’s structured, high-resolution research corpus, with relevant compound research, dosing logic, clinical and pre-clinical data selected for each question and routed through a proprietary systems-biology knowledge graph.
FoxAI’s epistemology applies the same scrutiny across clinical trial data, pre-clinical mechanistic research, and real-world evidence, while recognizing that each methodology answers different questions. Clinical trial results are interpreted through the lens of the studied population by preserving granular longitudinal cohort data rather than collapsing the study to the headline endpoint results.
ChatGPT, Gemini, and Claude do not have access to FoxAI’s corpus of high-resolution data, systems-biology knowledge graph, calculation engines, or pharmacokentic models. As a consequence, general-purpose AI systems commonly produce lower-resolution answers in this domain because their default synthesis privileges the published institutional pipeline, rarely interrogates pharmaceutical-sponsored trials at equivalent resolution, and discounts evidence generated outside that pipeline.
Reconstitution, dose-conversion, and drug-exposure calculations in FoxAI’s calculator tools are handled by deterministic engines rather than generated by the LLM. Drug-exposure and pharmacokinetic models are developed by the FoxAI Biomedical Research Team, with every model parameter, assumption, and derivation anchored to a referenced source.
Does PeptideFox sell research-use-only or compounded peptides?
No. PeptideFox publishes research and develops software. It does not manufacture, compound, prescribe, dispense, or sell research-use-only or compounded peptides.
Is PeptideFox independent?
PeptideFox is 100% independent with no external sponsors or investors. Its research standards, editorial conclusions, and assessments of vendors are not influenced by any outside party. PeptideFox does not actively pursue vendor affiliate relationships; a vendor must first pass all seven sourcing criteria and further validation, including a tour of U.S. manufacturing facilities, to be considered for any affiliate partnership.
Does PeptideFox independently evaluate peptide vendors?
PeptideFox evaluates vendors against seven published criteria: verifiable purity, measured vial quantity, current lab reports, endotoxin testing, historical batch records, a physical business address, and U.S. manufacturing. Reports are checked through the issuing laboratory when a verification portal is available. PeptideFox does not perform independent laboratory testing on vendor products; the full method is documented in the sourcing guide.
One hedges. One helps inform.
Generalist AIs default to a defensive register on anything pharmacological. FoxAI is built on PeptideFox's research corpus — it returns the structured answer a practitioner would assemble by hand.
$ Does retatrutide cause a HR spike or GI side effects at a low dose?...Probably not a major HR spike orsevere GI at 1 mg — but nobody canguarantee you won’t notice anything. From the clinical data: • Side effects are dose-dependent • 1 mg was the lowest dose studied • HR rise was dose-dependent too → per NEJM 2023 · NEJMoa2301972 At 1 mg weekly: • A mild HR increase is possible • Mild nausea/constipation possible • Severe events are less expected • Individual sensitivity varies To estimate better, tell me: 1. Prior semaglutide / tirzepatide? 2. Your current resting HR? 3. Is 1 mg your first-ever dose?
$ Does retatrutide cause a HR spike or GI side effects at a low dose?...HEART RATE — the thing to watch • Lean, Phase 1: +7.6 bpm at 0.3 mg • Lean, Phase 1: +10.3 bpm at 1 mg • Obese, steady state: +0.7 bpm only • Weight loss resets autonomic tone • Leaner users don’t get that offset GI — typically mild here • GIP ~48% engaged by 1 mg, fast arm • GIP brakes nausea, doesn’t cause it • GLP-1 (nausea driver): only ~7% • Nausea ~14% at 1 mg, near placebo BOTTOM LINE • Gut milder than expected — GIP helps • HR signal is real for leaner bodies • Not a wait-for-high-dose concern
Medical Disclaimer
The content in this site is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.